Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) has a pharmacologically complex interaction profile rooted in three distinct metabolic pathways — one per component of the fixed-dose tablet. Understanding these mechanisms is essential for managing co-administered therapies safely: some combinations carry absolute contraindications with life-threatening consequences, while others require only dose limits or laboratory surveillance. This page is a clinical reference covering the pharmacokinetic mechanisms, AUC data, and prescribing frameworks for each interaction category documented in the Biktarvy prescribing information and 2026 HIV treatment guidelines. For patient-facing guidance on supplement timing and dietary interactions, see our foods and dietary interactions guide.
How Biktarvy Is Metabolized: The Three Pharmacokinetic Pathways
- Bictegravir (BIC) is metabolized primarily by CYP3A4 and UGT1A1. Inducers of these enzymes lower bictegravir plasma concentrations — in severe cases to subtherapeutic levels insufficient to suppress HIV replication.
- Tenofovir alafenamide (TAF) is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). TAF also inhibits BCRP at the intestinal and hepatic level, which increases systemic exposure of co-administered BCRP substrates — most notably certain statins.
- Emtricitabine (FTC) undergoes renal elimination via organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins (MATE1, MATE2-K). FTC and BIC together inhibit these transporters, raising plasma concentrations of renally cleared co-drugs — particularly metformin and dofetilide.
The two highest-risk interaction categories: First, drugs that strongly induce CYP3A4 (principally rifampin) can reduce bictegravir AUC by up to 75%, driving plasma levels below the protein-adjusted IC90 and creating conditions for viral rebound and integrase resistance. Second, drugs eliminated by MATE1/MATE2-K (particularly dofetilide) accumulate to toxic concentrations when these transporters are inhibited — a mechanism that carries a risk of fatal arrhythmia.
Pharmacokinetic Data: Documented AUC Changes
| Co-administered Drug | Effect on Biktarvy Components | Effect on Co-Drug | AUC Change |
|---|---|---|---|
| Rifampin | Strong CYP3A/P-gp induction | — | BIC AUC ↓75% |
| Carbamazepine | CYP3A induction | — | BIC AUC ↓69% |
| Rifabutin | Moderate CYP3A/P-gp induction | — | BIC AUC ↓38% |
| Antacids (simultaneous) | Chelation in GI lumen | — | BIC AUC ↓33% |
| Dofetilide | — | MATE1/MATE2-K inhibition raises dofetilide exposure | Absolute contraindication |
| Metformin | — | OCT2/MATE inhibition raises metformin concentration | Metformin AUC ↑79% |
| Atorvastatin | — | TAF-mediated BCRP inhibition | Atorvastatin AUC ↑37% |
| Rosuvastatin | — | TAF-mediated BCRP inhibition | Rosuvastatin AUC ↑32% |
| St. John’s Wort | CYP3A4/P-gp induction | — | Absolute contraindication |
| Warfarin | — | Variable pharmacokinetic interaction | Monitor INR |
Contraindicated Drugs: Mechanisms and Clinical Consequences
The following drugs cannot be co-administered with Biktarvy. If a patient on Biktarvy requires one of these agents, a full antiretroviral regimen review and planned switch must occur before the interacting drug is initiated.
| Drug | Drug Class | Pharmacokinetic Mechanism | Clinical Consequence |
|---|---|---|---|
| Rifampin (Rifadin) | Anti-tuberculosis / Antibiotic | Strong CYP3A4 and P-gp inducer — reduces bictegravir AUC ~75% | HIV treatment failure + integrase resistance |
| Rifapentine (Priftin) | Anti-tuberculosis | Strong CYP3A4 and P-gp inducer — parallel mechanism to rifampin | HIV treatment failure + integrase resistance |
| St. John’s Wort | Herbal / Botanical | CYP3A4 and P-gp inducer — bictegravir falls to subtherapeutic levels | HIV treatment failure + integrase resistance |
| Dofetilide (Tikosyn) | Class III Antiarrhythmic | FTC and BIC inhibit renal MATE1 and MATE2-K transporters, raising dofetilide to QT-prolonging levels | Life-threatening ventricular arrhythmia (TdP) |
Major Interactions: Dose Adjustments, Monitoring, and Clinical Management
| Drug / Class | Status | Effect | Recommended Action |
|---|---|---|---|
| Antacids (Al, Mg, Ca, Fe, Zn) | Timing required | Chelation reduces bictegravir GI absorption; BIC AUC ↓33% | Separate by ≥2 hours (either direction) |
| Carbamazepine | Not recommended | CYP3A inducer — bictegravir AUC ↓~69% | Switch to lamotrigine or levetiracetam |
| Oxcarbazepine | Not recommended | CYP3A inducer | Switch to safer anticonvulsant |
| Phenobarbital / Primidone | Not recommended | CYP3A inducer | Switch to safer anticonvulsant |
| Phenytoin / Fosphenytoin | Not recommended | CYP3A inducer | Switch to safer anticonvulsant |
| Rifabutin | Not recommended | Moderate CYP3A/P-gp inducer — bictegravir AUC ↓~38% | Regimen switch recommended |
| Metformin | Dose cap applies | OCT2/MATE inhibition raises metformin AUC ~79%; lactic acidosis risk | Limit to ≤1,000 mg/day; monitor eGFR |
| Atorvastatin | Dose cap applies | TAF BCRP inhibition raises atorvastatin AUC ~37%; myopathy risk | Initiate at 10 mg; maximum 40 mg/day |
| Rosuvastatin | Dose cap applies | BCRP inhibition raises rosuvastatin AUC ~32%; myopathy risk | Initiate at 5 mg; maximum 20 mg/day |
| Simvastatin / Lovastatin | Avoid if possible | CYP3A4 + BCRP effects compound statin exposure | Prefer pravastatin or pitavastatin |
| Warfarin | Monitor INR | Variable pharmacokinetic interaction | Check INR within 1–2 weeks of starting/stopping Biktarvy |
| Hormonal contraceptives | No interaction | No clinically significant interaction identified | No dose adjustment required |
| Methadone | No interaction | No clinically significant interaction identified | No dose adjustment required |
| Buprenorphine / naloxone | No interaction | No clinically significant interaction documented | No dose adjustment required |
Chelation Pharmacokinetics: How Polyvalent Cations Impair Bictegravir Absorption
Bictegravir contains a metal-chelating pharmacophore — specifically a diketo acid moiety — that coordinates with polyvalent metal ions in the gastrointestinal lumen. When bictegravir is present simultaneously with divalent or trivalent cations (Ca²+, Mg²+, Al³+, Fe²+/Fe³+, Zn²+), stable insoluble chelate complexes form before intestinal absorption can occur.
Pharmacokinetic data show that simultaneous co-administration with aluminum/magnesium hydroxide antacids reduces bictegravir AUC by approximately 33% and Cmax by a similar margin. Separating administration by at least two hours — in either direction — eliminates the chelation window and restores bictegravir AUC to expected values.
Anticonvulsants: CYP3A4 Induction Risk and Preferred Alternatives
Anticonvulsants Not Recommended With Biktarvy
- Carbamazepine (Tegretol, Carbatrol) — strong CYP3A4 inducer; bictegravir AUC ↓~69%
- Oxcarbazepine (Trileptal) — moderate CYP3A4 inducer; not recommended
- Phenobarbital and primidone (Mysoline) — CYP3A4/2C9/2C19 inducer; not recommended
- Phenytoin and fosphenytoin (Dilantin, Cerebyx) — CYP3A4/2C9 inducer; not recommended
Preferred Anticonvulsant Alternatives
- Lamotrigine (Lamictal) — UGT glucuronidation, minimal CYP3A4 involvement; no clinically significant effect on bictegravir
- Levetiracetam (Keppra) — renally cleared; no CYP involvement; no Biktarvy interaction
- Gabapentin (Neurontin) — excreted renally unchanged; no CYP3A4 induction
Prescribing coordination: Any anticonvulsant change in a patient on Biktarvy requires coordination between neurology and infectious disease. Abrupt anticonvulsant withdrawal carries independent seizure risk.
Statins and BCRP Inhibition
- Atorvastatin: BCRP substrate — AUC ↑37% with Biktarvy. Initiate at 10 mg; maximum 40 mg/day.
- Rosuvastatin: BCRP and OATP1B substrate — AUC ↑32% with Biktarvy. Initiate at 5 mg; maximum 20 mg/day.
- Simvastatin / Lovastatin: Avoid where clinically possible due to compounded CYP3A4 + BCRP effects.
- Pravastatin: Minimal BCRP involvement. Preferred first-line statin when potency requirements permit.
- Pitavastatin: Low BCRP interaction profile. Preferred alternative when high-intensity therapy is needed.
Metformin and Renal Transporter Inhibition
Metformin is eliminated almost exclusively by active renal secretion via OCT2 and MATE1/MATE2-K. Both bictegravir and emtricitabine inhibit these transporters, raising steady-state metformin concentrations by approximately 79%. Management: cap metformin at 1,000 mg per day; establish baseline eGFR before initiating; reassess every 3–6 months.
St. John’s Wort: Absolute Contraindication
St. John’s Wort is absolutely contraindicated with Biktarvy. Reduction of bictegravir to subtherapeutic plasma concentrations creates conditions for HIV replication under partial integrase inhibition pressure. Viral variants selected under these conditions may carry integrase resistance mutations that confer cross-resistance to other integrase strand transfer inhibitors including dolutegravir and raltegravir.
Laboratory Monitoring by Co-Medication Category
| Co-Medication | Primary Monitoring Parameter | Recommended Timing |
|---|---|---|
| Metformin | eGFR; serum lactate if symptoms develop | Baseline eGFR before initiating; repeat every 3–6 months |
| Warfarin | INR (prothrombin time) | Within 1–2 weeks of starting or stopping Biktarvy |
| Atorvastatin / Rosuvastatin | Creatine kinase (CK); muscle symptom assessment | Baseline CK before initiating the statin; repeat with any new myalgia |
| Rifabutin (if clinically necessary) | HIV viral load | Monthly viral load for first 3 months; quarterly thereafter |
| All patients on Biktarvy (routine) | eGFR, creatinine, urine protein/glucose; LFTs; lipid panel; HIV viral load; CD4 count | Every 3–6 months per standard HIV treatment monitoring guidelines |
Frequently Asked Questions
Rifampin is one of the most potent inducers of CYP3A4 and P-glycoprotein in clinical use. Both systems are central to bictegravir pharmacokinetics: CYP3A4 is the primary metabolic enzyme and P-gp is the intestinal efflux transporter. Combined induction reduces bictegravir plasma AUC by approximately 75%, dropping concentrations below the protein-adjusted IC90 needed for full integrase inhibition. HIV replication resumes under partial INSTI pressure — the precise pharmacodynamic condition that selects for integrase resistance mutations at N155H and Q148K/R/H, which can confer cross-resistance across the entire INSTI class.
Dofetilide is eliminated almost entirely by active renal secretion via MATE1 and MATE2-K transporters — the same renal efflux transporters that emtricitabine and bictegravir both inhibit. The resulting increase in dofetilide plasma concentrations extends its QT-prolonging effect; at elevated concentrations this produces excessive QT interval prolongation that precipitates torsades de pointes. Because dofetilide has an extremely narrow therapeutic index, there is no established dose adjustment that renders co-administration safe.
The primary investigation is renal function: eGFR and serum creatinine should be established at baseline and reassessed every 3–6 months. Biktarvy’s inhibition of OCT2 and MATE transporters raises metformin AUC by approximately 79%, and metformin accumulation is most likely in patients with compromised renal elimination. Serum lactate should be obtained urgently if the patient presents with unexplained fatigue, nausea, vomiting, abdominal pain, dyspnea, or cold extremities.
Bictegravir requires sustained concentrations above the protein-adjusted IC90 to maintain full occupancy of the HIV integrase active site. When CYP3A4-inducing drug interactions reduce bictegravir below this threshold, integrase is only partially inhibited and HIV replication continues. Variants with substitutions reducing bictegravir binding affinity — at N155, Q148, and E92 — are selectively enriched under drug pressure. The Q148K/R/H pathway is of particular concern because it produces broad cross-resistance to dolutegravir and raltegravir.
Pravastatin and pitavastatin carry the lowest interaction burden. When atorvastatin or rosuvastatin are clinically indicated, they can be used within dose caps (atorvastatin ≤40 mg/day; rosuvastatin ≤20 mg/day) with baseline CK documentation. Simvastatin and lovastatin should be avoided due to compounded CYP3A4 and BCRP effects.
Not with standard rifamycin-based TB therapy. Rifampin is absolutely contraindicated with Biktarvy due to a 75% reduction in bictegravir AUC sufficient to cause HIV treatment failure and resistance development. Rifabutin is not recommended either (38% AUC reduction). Current DHHS and WHO guidelines recommend a planned switch to a dolutegravir-based antiretroviral regimen before beginning rifamycin treatment.
This article was reviewed by Dr. Ranjit Mohan, MD, and written by Ray Ashton in accordance with SunnyPharma’s Editorial Policy. Content is reviewed for clinical accuracy, updated when guidelines change, and written to inform — not replace — the advice of a qualified healthcare provider.
References
- Gilead Sciences. Biktarvy US Prescribing Information. January 2024.
- DHHS Panel on Antiretroviral Guidelines. Updated January 2025. clinicalinfo.hiv.gov
- University of Liverpool HIV Drug Interaction Database. Accessed March 2026.
- Tseng A, et al. Drug–drug interactions between antiretrovirals and co-administered agents. Ther Drug Monit. 2023;45(1):14–35.
- World Health Organization. Guidelines for Treatment of Drug-Susceptible Tuberculosis. 2022. who.int